Takeaways from Davos: Business leaders see no recession in 2024, and few want to talk about Israel
https://www.cnbc.com/2024/01/19/takeaways-from-davos-wef-2024-us-recession-ai-china-economy.html
Jan 19, 2024 - The annual World Economic Forum is wrapping up in Davos, Switzerland, and key takeaways include predictions about a U.S. recession and AI.
0
Wall Street Analysts See Alibaba (BABA) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2212784/wall-street-analysts-see-alibaba-baba-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2212784
Jan 19, 2024 - The average brokerage recommendation (ABR) for Alibaba (BABA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
0
The One Part of the Vision Pro That Apple Doesn’t Want You to See
https://www.wired.com/story/one-part-of-apple-vision-pro-apple-doesnt-want-you-to-see/
Jan 18, 2024 - Apple’s latest series of Vision Pro demos carefully obscures one important hardware feature.
0
Stock And Mixed Assets ETFs Attract Record Net Inflows In December While Mutual Funds See Redemptions
https://seekingalpha.com/article/4663622-stock-and-mixed-assets-etfs-attract-record-net-inflows-in-december?source=feed_tag_etf_portfolio_strategy
Jan 18, 2024 - Mutual fund investors withdrew $86.0 billion in December, while money market funds saw net inflows. Click here to read our most recent report.
0
Lilly, Novo Nordisk diabetes drugs see price raises - report
https://seekingalpha.com/news/4056146-lilly-novo-nordisk-diabetes-drugs-see-price-raises?source=feed_sector_healthcare
Jan 18, 2024 - Popular diabetes medicines Mounjaro and Ozempic, as well as other drugs, saw list price increases this month. Read more here.
0
Roma Green IPO Underwhelms As Investors Fail To See Green In Its ESG Story
https://seekingalpha.com/article/4663527-roma-green-ipo-underwhelms-as-investors-fail-to-see-green-in-esg-story?source=feed_tag_ipo_analysis
Jan 18, 2024 - Roma Green priced its shares at $4, representing the bottom of their target range, in a New York IPO that raised about $9.8 million in gross proceeds.
0
VALE S.A. (VALE) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2211764/vale-s-a-vale-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211764
Jan 17, 2024 - VALE S.A. (VALE) concluded the recent trading session at $14.06, signifying a -1.75% move from its prior day's close.
0
Ericsson (ERIC) Sees a More Significant Dip Than Broader Market: Some Facts to Know
https://www.zacks.com/stock/news/2211743/ericsson-eric-sees-a-more-significant-dip-than-broader-market-some-facts-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2211743
Jan 17, 2024 - Ericsson (ERIC) closed the most recent trading day at $6.05, moving -0.82% from the previous trading session.
0
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
https://www.zacks.com/stock/news/2211467/wall-street-analysts-see-a-27-5-upside-in-revolution-medicines-inc-rvmd-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2211467
Jan 17, 2024 - The mean of analysts' price targets for Revolution Medicines, Inc. (RVMD) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
0
Wall Street Analysts See Chipotle (CMG) as a Buy: Should You Invest?
https://www.zacks.com/stock/news/2211428/wall-street-analysts-see-chipotle-cmg-as-a-buy-should-you-invest?cid=CS-ZC-FT-fundamental_analysis|average_broker_rating-2211428
Jan 17, 2024 - According to the average brokerage recommendation (ABR), one should invest in Chipotle (CMG). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
0